AJINOMOTO CO., INC.

NJ Bio and Ajinomoto Bio-Pharma Services Partner to Advance Antibody-Drug Conjugate Development Through AJICAP™ Platform Integration

- NJ Bio, Inc. and Ajinomoto Bio-Pharma Services announced a research collaboration to integrate the AJICAP™ site-specific conjugation platform into NJ Bio's discovery and development workflows for antibody-drug conjugates. - The AJICAP™ platform enables precise chemical modification at defined lysine residues without antibody engineering, preserving structure and functionality while improving pharmacokinetics and therapeutic index. - This partnership strengthens NJ Bio's position as a comprehensive partner for biopharmaceutical companies, offering end-to-end support from early drug design through preclinical development. - The collaboration is expected to reduce development risk, shorten timelines, and improve project outcomes for next-generation targeted therapeutics.